Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study

NCT07161167 | Not Yet Recruiting

• 1 other identifier: obesity-related cancer & BC
• Study Type: observational
• Target: 6,743
• Locations: 1 country
• Sites: 1

Brief Summary

Over the past 20 years, China's obesity rates have surged, increasing cancer burden. Obesity links to 13 cancers via metabolic effects of visceral fat and insulin resistance, while sarcopenic obesity (BMI-independent) may worsen outcomes. Traditional BMI lacks precision; advanced methods (e.g., BIA/CT) are needed. Existing studies show inconsistent results, possibly due to heterogeneity. This multicenter prospective cohort study uses imaging to assess body composition changes (fat/muscle) in obesity-related tumors and their impact on survival, recurrence, and quality of life, and explore the underlying mechanism.

Conditions

Obesity Rekated Cancer; Body Composition Changes; Survival; Mechanism

Outcome Measures

Primary Outcomes (1)

• Overall survival

  The time from the start of follow-up to death (for any reason).

  From date of diagnosis until the date of death from any cause, assessed up to 10 years

Secondary Outcomes (2)

• Progression-free survival after diagnosis

  From date of diagnosis until the date of first documented progression , assessed up to 10 years

• Time of recurrence and/or distant metastasis after diagnosis

  From date of diagnosis until the date of first documented recurrence and/or distant metastasis, whichever came first, assessed up to 10 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Study participants will be enrolled if they are under clinical care in oncology-related departments

You may qualify if:

• Age ≥18 years, regardless of gender.
• Histologically or cytologically confirmed obesity-associated malignant tumors (e.g., breast cancer, colorectal cancer, gastric cancer, lung cancer, or thyroid cancer) with planned treatment after diagnosis (any treatment modality permitted).
• No prior chemotherapy, radiotherapy, biologic therapy, immunotherapy, or other antitumor treatments for malignancy.

You may not qualify if:

• Patients with concurrent non-obesity-related malignancies.
• History of prior malignancy (except completely cured carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin).
• Patients with concurrent multiorgan dysfunction syndrome, autoimmune diseases, infectious diseases, neurological disorders, or psychiatric disorders.

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead

Study Sites (1)

Peking union medical college hospital

Beijing, Beijing Municipality, 100730, China

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 21, 2025
• First Posted: September 8, 2025
• Study Start: September 15, 2025
• Primary Completion (Estimated): September 30, 2030
• Study Completion (Estimated): September 30, 2030
• Last Updated: September 8, 2025

Record last verified: 2025-07

Locations

CN (1)